Finance
Novavax says, the US Food and Drug Administration (FDA) has granted expanded emergency use authorization for its Covid-19 vaccine Adjuvanted for adolescents aged 12 to 17 years.
According to the dpa news agency, the vaccine is the first protein-based Covid-19 vaccine approved in the United States.
According to the company, doses of the Adjuvanted are now available for use in adolescents based on the Centers for Disease Control and Prevention’s (CDC) recommendation.
The FDA granted emergency use authorization for a two-dose primary series in adults aged 18 years and older in July 2022, following a recommendation from the CDC Advisory Committee on Immunisation Practices and CDC endorsement.
Source:OCN
